Restful. Nights.

With Genio®, Nyxoah has reinvented sleep for patients with moderate to severe Obstructive Sleep Apnea (OSA). Genio® is an easy-to-use, comfortable and efficient sleep apnea treatment that provides users the freedom to enjoy a restful sleep and live their life to the fullest again.

Discover Genio
bubble
bubble
bubble
bubble
bubble

We are Nyxoah

Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

What is Obstructive Sleep Apnea

 

OSA and health risks

OSA is the most common sleep disordered breathing condition, affecting globally around 936 million people between 30 and 69 years of age, of whom 425 million suffer from moderate to severe OSA, requiring treatment*.

Left untreated, OSA is associated with increased mortality risk* and comorbidities, including cardiovascular diseases, depression and stroke.

Clinical studies have shown that the mortality rate of non-treated patients suffering from OSA increases significantly over time* . Untreated OSA is associated with a two-times more risk of stroke* and five-times more risk of cardiovascular mortality*. OSA increases the risk of heart failure by 140%*.

Nyxoah in the news

24th June, 2020

Nyxoah receives IDE approval from the U.S. Food and Drug Administration (FDA) for its DREAM study

Read more

9th March, 2020

Successful first implantation of two patients in Benelux with the Genio® system

 

Read more

12th Feb, 2020

Nyxoah raises €25 million in private funding round

 

Read more

Discover Genio®

A sleep solution by Nyxoah 

Discover Genio®

All rights reserved © 2020 Nyxoah S.A. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah S.A. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020

bubble
bubble
bubble
bubble
bubble